Print

TONIX Pharmaceuticals, Inc. Announces Completion of Clinical Trial of Sublingual TNX-102  
7/30/2012 9:52:22 AM

NEW YORK--(BUSINESS WIRE)--Tonix Pharmaceuticals Holding Corp. (OTCBB: TNXP) (“TONIX” or the “Company”), a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system (“CNS”), including fibromyalgia syndrome (“FM”) and post-traumatic stress disorder (“PTSD”), announces that the clinical portion of a human study of a solution version of TNX-102 2.4 mg sublingual tablets (“TNX-102 SL”) has completed. TNX-102 is TONIX’s very low dose form of cyclobenzaprine, which the Company is developing as a first-in-class medication for the management of FM.
//-->